Bioventus Inc. Class A Common Stock
BVSBioventus Inc. Class A (BVS) is a global leader in orthobiologic solutions dedicated to helping patients recover faster from injuries and surgeries. The company develops and commercializes innovative therapies in areas such as bone healing, joint health, and pain management, with a focus on bone graft substitutes, bioactive solutions, and regenerative products to improve patient outcomes.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 31, 2004 | $0.61 | 2004-03-26 | 2004-03-30 |
| December 31, 2003 | $0.61 | 2003-12-26 | 2003-12-30 |
Dividends Summary
- Consistent Payer: Bioventus Inc. Class A Common Stock has rewarded shareholders with 2 dividend payments over the past 1 years.
- Total Returned Value: Investors who held BVS shares during this period received a total of $1.22 per share in dividend income.
- Latest Payout: The most recent dividend of $0.61/share was paid 8144 days ago, on March 31, 2004.
- Dividend Growth: Since 2003, the dividend payout has grown by 0.0%, from $0.61 to $0.61.
Company News
Bioventus Inc. announced that Mark Singleton, Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The presentation will be webcast live and available for replay on the company's investor website.
Conexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) sub...
The global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market ...
Bioventus secured a new $400 million credit agreement, replacing its previous 2019 credit facilities, which reduces interest expenses and increases liquidity from $40 million to $100 million in revolving credit.
The global intramedullary nail market is expected to grow rapidly, driven by the rising incidence of bone fractures, particularly among the aging population, and advancements in surgical techniques. However, the market faces challenges such as high procedural costs, the need for skilled professionals, and competition from alternative fixation dev...
